Some general counsel might conclude that if they undertake an innovative, daring, and massive restructuring of their economic relationship with outside counsel, they should keep it quiet. One reason might be that a competitive advantage should not be bruited about. Another reason could be caution; new ideas often go blooie, so why advertise a potential misstep?
Not so with Amy Schulman, the general counsel of Pfizer, who seems to have held back nothing in Corp. Counsel, Vol. 17, Jan. 2010 at 66. The article pours out facts, dates, and specifics. It is a recipe for one technique to “slash its domestic legal spending by 15-20 percent.
Here is the whispered question. Is Pfizer altruistically becoming the poster child for change? Is Schulman courageously trying to drive industry-wide change?